Delivery Order SPE2DB20D3103-SPE2DB23FL4M3
- Not listed
- This federal contract award, valued at $22,592.18, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Dupixent 300 mg/2 ml syringes, a pharmaceutical product, with a completion date of May 3, 2023. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00, which serves as the primary vehicle for the company to deliver...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Dupixent 200 mg/1.14 ml syringes. The $52,992.43 firm fixed-price delivery order was placed by the Defense Logistics Agency (DLA) Troop Support Medical. The contract has an ultimate completion date of February 8, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the...
- This federal contract award, valued at $2,441.35, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the delivery of Dupixent 200 mg/1.14 ml syringes, a specialty pharmaceutical product, with a completion date of December 8, 2023. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as...
- This federal contract award, valued at $8,258.67, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract provides for the delivery of Dupixent 300 mg/2 ml syringes, a specialty pharmaceutical product, to support federal healthcare programs. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract has a ceiling value of $9,928.69 and is a delivery order for the supply of Dupixent 300 mg/2 ml syringes. The contract is a firm fixed-price type with a period of performance through May 7, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a wholly-owned subsidiary of Cencora, Inc. The $20,066.18 firm-fixed-price delivery order is for the pharmaceutical product Dupixent 300 mg/2 ml syringe. The contract has an ultimate completion date of May 1, 2024 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The award, valued at $14,402.52, is for the delivery of the pharmaceutical product Dupixent 300 mg/2 ml syringe, 2 ml. The contract is a Firm Fixed Price Delivery Order, with a period of performance ending on May 1, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This federal contract award was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $31,160.74 firm fixed-price delivery order is for the supply of Dupixent 300 mg/2 ml syringes, a specialty pharmaceutical product. The contract has a completion date of May 11, 2023. Amerisourcebergen Drug Corp holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract, valued at $4,957.05, is a delivery order for the pharmaceutical product Dupixent 200 mg/1.14 ml syringe. The award has no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $2,389.04 firm fixed-price delivery order is for the pharmaceutical product Dupixent 300 mg/2 ml syringe and has an ultimate completion date of January 24, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB23FL4M3Delivery Order
This federal contract award, valued at $11,612.16, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Dupixent 300 mg/2 ml syringes, a specialty pharmaceutical product, to support federal healthcare programs. The contract is a firm-fixed-price delivery order with an ultimate completion date of October 27, 2022. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. This contract award is not designated with any set-aside requirements, indicating open competition. Amerisourcebergen also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.6k | 10/26/22 |